CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

CDC Explains and Defends Molecular Surveillance System

A leading researcher at the Centers for Disease Control and Prevention addressed community concerns that surveillance data will be used to put people in prison under HIV criminalization laws.

By Martha Kempner

Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives

Panelists at CROI 2018 painted a bleak picture of the scale of the country's addiction crisis, noting that the never-before-seen dynamics of the current drug epidemic require creative approaches to HIV treatment and prevention among people who inject...

By Sony Salzman

New Study Shows Women's HIV Risk Triples During Pregnancy, Quadruples Postpartum

Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.

By Sony Salzman

More Women Must Be Included in Academia and in Clinical Trials, Panelists Demand

Presentations on women in research at this year's Conference on Retroviruses and Opportunistic Infections highlighted the lack of inclusion, offered ideas on how to remedy the situation, and showed how one woman moved from advocate to researcher.

By Barbara Jungwirth

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.

By Polly Clayden for HIV i-Base

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

By Polly Clayden for HIV i-Base

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults

Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.

By Polly Clayden for HIV i-Base

World Health Organization Pediatric Dosing Tool

A pediatric dosing tool developed by the World Health Organization might assist in the design of clinical trials for dosing in children.

By Polly Clayden for HIV i-Base

Harnessing Vaginal Microbiota to Protect Women From HIV: What We Know and Don't Know

If you're a provider, you want to offer patients the latest, evidence-based ways to reduce their risk for HIV -- including women who may have increased risk because of the microbes in their genital tracts.

By Heather Boerner

Early Diagnosis and Treatment in Infants Is Challenging

"Even if we have the best drug, it cannot do anything if we don't have all [the social] aspects together," says Bindiya Meggi, M.Sc.

By Barbara Jungwirth